InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
January 10, 2022 07:30 ET
|
InflaRx N.V.
Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:...
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
January 05, 2022 08:00 ET
|
InflaRx N.V.
Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D...
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
January 05, 2022 07:30 ET
|
InflaRx N.V.
Phase III study to include a new primary endpoint, the modified HiSCRNew primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rdPhase III program...
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
November 15, 2021 07:30 ET
|
InflaRx N.V.
Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients: vilobelimab demonstrated comparable efficacy to standard of careUse of vilobelimab instead...
InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference
November 11, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Third Quarter 2021 Financial & Operating Results
November 05, 2021 07:30 ET
|
InflaRx N.V.
Feedback received from FDA supportive of new primary endpoint measuring reductions in all three inflammatory Hidradenitis Suppurativa (HS) lesions for Phase III program with vilobelimab in HSIn Phase...
InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference
November 03, 2021 07:30 ET
|
InflaRx N.V.
JENA, GERMANY, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
October 27, 2021 07:30 ET
|
InflaRx N.V.
6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the highest dose cohortTreatment was well tolerated; no dose-related adverse events observedFinal...
InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19
October 19, 2021 07:30 ET
|
InflaRx N.V.
Initial portion of the grant amounts to EUR 25.8 millionRemainder of the grant will be awarded in three additional milestone-dependent tranches JENA, Germany, Oct. 19, 2021 (GLOBE NEWSWIRE) --...
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
October 12, 2021 07:30 ET
|
InflaRx N.V.
Study has enrolled 369 patients across 9 countriesTopline results expected to be available in Q1 2022 JENA, Germany, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage...